ArticleScientific reports2024
Antibacterial activity of green synthesized copper oxide nanoparticles against multidrug-resistant bacteria.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Metal oxide nanoparticles for acne vulgaris: mechanisms, synthesis, formulation, and translational prospects.RSC advances · 2026Review
- Biologically Mediated Nanoparticle Synthesis as a Potential Green Strategy: Principles, Methods, and Pharmaceutical Applications.Pharmaceutics · 2026Review
- Green Fabrication and Characterization of Copper Oxide Nanoparticles Using C. Gigantea Leaf Extract and Their ROS-Mediated Anticancer Activity Against A549 Lung Cancer Cells.Cell biochemistry and biophysics · 2026Article
- Copper/Copper Oxide Nanoparticles: Biological Synthesis, Characterization and Potential Biomedical Applications: Advances and Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Novel Antimicrobial Composites Modified with Nanosilver, CuSOMaterials (Basel, Switzerland) · 2026Article
- Green Hydrothermal Synthesis of CuO-NPs and CuO-NPs@Alhagi Maurorum for Combating Multidrug Resistant Bacterial Infections.Biological trace element research · 2026Article
- Antimicrobial and antioxidant properties of green synthesis CuO nanoparticles usingIranian journal of microbiology · 2026Article
- A Composite Based onPolymers · 2026Article
- Novel CTAB-Assisted Synthesis of MgO Nanoparticles from Piper longum Leaves: Structural Insights and Hirshfeld Surface Analysis with Bioactivity Evaluation.Applied biochemistry and biotechnology · 2026Article
- Article
- A Comprehensive Review on Copper Oxide Nanoparticles: Physicochemical Parameters, Pharmacological Potential and Pathophysiological Effects.International journal of nanomedicine · 2026Review
- Recent advances in phyto- and microorganisms-mediated synthesis of copper nanoparticles and their emerging applications in healthcare, environment, agriculture and food industry.Bioprocess and biosystems engineering · 2025Review
- Harnessing copper oxide nanoparticles for advanced photocatalytic, antimicrobial, and larvicidal applications.Scientific reports · 2025Article
- Shikonin-copper coordination nanoparticles for enhanced antibacterial and antibiofilm activity against Staphylococcus aureus.Scientific reports · 2025Article
- Green Synthesis of Copper Nanoparticles from Kiwi Peel: Antibacterial Properties and the Role of MexY Gene Expression in Pseudomonas aeruginosa Efflux Pumps.Applied biochemistry and biotechnology · 2025Article
- Characterization and Performance Evaluation of Cotton Fabrics Functionalized via In Situ Green Synthesis of Silver Nanoparticles UsingPolymers · 2025Article
- Antibacterial effect and MexA efflux pump Inhibition by green-synthesized copper nanoparticles from Mentha piperita.Molecular biology reports · 2025Article
- Combating Healthcare-Associated Infections in Modern Hospitals: Nanotechnology-Based Approaches in the Era of Antimicrobial Resistance.Nanomaterials (Basel, Switzerland) · 2025Review
- Thermal annealing modulates the structural, optical, and antibacterial properties of Cu-based nanoparticles.RSC advances · 2025Article
- Biogenic copper and copper oxide nanoparticles to combat multidrug-resistantBiotechnology reports (Amsterdam, Netherlands) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using plant extracts in the green synthesis of nanoparticles has become an environmentally acceptable approach. In our study, copper oxide nanoparticles (CuO NPs) were synthesized using ethanolic extracts of Azadirachta indica and Simmondsia chinensis. CuO NP formation was confirmed by the change in color and by UV‒visible spectroscopy (CuO NPs peaked at a wavelength of 344 nm). TEM images confirmed the semispherical shape of the CuO NPs, with particle sizes ranging from 30.9 to 10.7 nm. The antibacterial activity of these NPs was evaluated by using the agar diffusion method against clinical isolates, including methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli, Pseudomonas aeruginosa, Acinetobacter spp., Klebsiella pneumoniae, and Stenotrophomonas maltophilia. The minimum inhibitory concentration (MIC) of CuO NPs ranged from 62.5 to 125 µg/ml. In contrast, the antioxidant activity and antibiofilm activity of CuO NPs ranged from 31.1 to 92.2% at 125-500 µg/ml and 62.2-95%, respectively, at 125 -62.5 µg/ml. Our results confirmed that CuO NPs had IC50s of 383.41 ± 3.4 and 402.73 ± 1.86 at 250 µg/mL against the HBF4 cell line. Molecular docking studies with CuO NPs suggested that penicillin-binding protein 4 (PBP4) and beta-lactamase proteins (OXA-48) strongly bind to S. aureus and K. pneumoniae, respectively, with CuO NPs. Our study confirms the promising use of CuO NPs in treating pathogenic bacteria and that CuO NPs could be possible alternative antibiotics. This study supports the pharmaceutical and healthcare sectors in Egypt and worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.